Stereotaxis Posts 20% Revenue Growth on Regulatory Wins, Eyes Manufacturing Scale-Up
Event summary
- Stereotaxis reported $32.4M in 2025 revenue, up 20% YoY, with Q4 revenue growing 36% to $8.6M.
- Achieved regulatory approvals for GenesisX robot, MAGiC ablation catheter, and MAGiC Sweep in the US and Europe.
- System backlog at the start of 2026 stands at $9.1M, with gross margins at 53% for the full year.
- Plans to ramp MAGiC catheter manufacturing to 500 units per month by year-end 2026.
- Anticipates double-digit revenue growth in 2026, targeting $40M in annual revenue.
The big picture
Stereotaxis is positioning itself as a leader in surgical robotics for minimally invasive endovascular intervention, leveraging recent regulatory approvals to drive commercial growth. The company's focus on scaling manufacturing and expanding its product ecosystem aligns with broader industry trends toward robotic precision and digital integration in the operating room. With a strong system backlog and improving gross margins, Stereotaxis aims to achieve sustained multi-year revenue growth.
What we're watching
- Manufacturing Ramp-Up
- Whether Stereotaxis can successfully scale production of MAGiC and GenesisX to meet commercial demand.
- Commercial Execution
- How quickly the company can transition electrophysiology customers to its new product portfolio.
- Regulatory Milestones
- The pace at which Stereotaxis advances its Synchrony Digital Surgery Suite through FDA approval.
Related topics